Auro Laboratories Limited is into the manufacturing of Active Pharmaceutical Ingredients (APIs), specializing in Diabetes therapy. The company also also undertakes Toll/Custom Manufacturing for API's and Intermediates on contract basis. Key API Products of Auro Labs are: - Metformin Hydrochloride - Chlorzoxzone - Chlorphenamine MaleateProduct Portfolio: a) Active Pharmaceutical Ingredients:...
Auro Laboratories Limited has completed its capacity expansion project for Metformin HCL and other products at its existing manufacturing unit. The plant is now fully operational again, which strengthens the company’s production capabilities and supports its growth prospects. This completion is a positive development for shareholders as it enhances the...
Auro Laboratories Limited has announced a board meeting to approve the financial results for the quarter and half-year. The company reported total income from operations of Rs. 2.21 lakh for the period with no profit or loss before and after tax. The announcement confirms ongoing compliance and transparency in its...
Auro Laboratories Limited has authorized its Whole Time Director, Siddhartha Deorah, as the key managerial personnel responsible for determining the materiality of company events and disclosures to stock exchanges. This centralization aims to streamline communication and ensure timely, consistent updates for investors and stakeholders. The designation underscores accountability in managing...
Auro Laboratories Limited has announced the Annual Secretarial Compliance Report for the financial year ended March 31, 2025, confirming adherence to key statutory provisions and corporate governance practices. The report highlights compliance with SEBI regulations, timely adoption and updating of policies, maintenance of an active website, and proper board evaluations....
Auro Laboratories has announced a board meeting to approve the financial results for the quarter and half-year. The company appointed Mr. Kuntal Pancholi as Chief Financial Officer, bringing over 29 years of experience, and engaged M/s. Pokharna and Associates as Internal Auditors for FY 2025-26. The financial results show total...
